On June 2, 2025, JP Morgan analyst Brian Cheng issued a report concerning Blueprint Medicines (BPMC, Financial), with key changes to both the stock's rating and price target.
BPMC, the ticker symbol for Blueprint Medicines, experienced a rating downgrade from "Overweight" to "Neutral" by JP Morgan. This shift reflects a more cautious stance from the analyst on the prospects of the company.
Additionally, the price target for BPMC was adjusted downward. The revised price target is now set at $129.00, a slight decrease from the previous target of $130.00. This represents a -0.77% change in price target as analyzed by Brian Cheng.
Investors and stakeholders are advised to consider these updates while making informed decisions regarding BPMC's stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Blueprint Medicines Corp (BPMC, Financial) is $122.00 with a high estimate of $150.00 and a low estimate of $83.00. The average target implies an downside of 4.43% from the current price of $127.66. More detailed estimate data can be found on the Blueprint Medicines Corp (BPMC) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Blueprint Medicines Corp's (BPMC, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Blueprint Medicines Corp (BPMC, Financial) in one year is $191.68, suggesting a upside of 50.15% from the current price of $127.655. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Blueprint Medicines Corp (BPMC) Summary page.
